KEAP1 and lung cancer: Meanwhile, deletion of KEAP1 in primary human T lymphocytes promotes Treg cell activation and can potentially be used for treating immune-related diseases [51] KEAP1 deletion also upregulates NRF2 downstream protein SLC7A11, causing the increase of NADPH consumption and glucose dependency in lung cancer cells [52].